Deals Of The Week: Allergan/Molecular Partners, Silence Therapeutics/MiReven, Pfizer/Mylan
Executive Summary
The widely dispersed array of developmental therapies for conditions such as non-small cell lung cancer and type 2 diabetes begs the question of whether it would make more sense to have a biopharmaceutical industry based on solution-focused companies approaching a single problem from multiple angles.
You may also be interested in...
Financial Crunch Time For Inspiration As Hemophilia Pact With Ipsen Gets Surprise Revamp
Inspiration Biopharma and hemophilia partner Ipsen have renegotiated their nearly three-year-old deal around two late-stage clinical assets. As part of the new deal, Ipsen has given up its option to buy Inspiration, providing the biotech with the opportunity – and the necessity – to find fresh financing from new backers in the coming months.
Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions
Allergan licenses a second novel product from Switzerland's Molecular Partners for ophthalmic indications and enters into a discovery alliance under which it has the option to license three further ophthalmic compounds.
Silence Therapeutics Raising $8.8M To Send RNAi Drug To Phase IIa
With a deeply discounted subscription and open share offering, the U.K.'s RNAi specialist, Silence Therapeutics, hopes to reach proof of concept with its lead product candidate.